Literature

Various publications since 2000 have been generated as precursor to our technology, or by using and improving the technologies.

Publications

  • Drexler JF, Kupfer B, Petersen N, Grotto RM, Rodrigues SM, Grywna K, Panning M, Annan A, Silva GF, Douglas J, Koay ES, Smuts H, Netto EM, Simmonds P, Pardini MI, Roth WK, Drosten C. A novel diagnostic target in the hepatitis C virus genome. PLoS Med. 2009 Feb 10;6(2):e31
  • Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ; German Red Cross NAT Study Group. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion. 2008 Aug;48(8):1558-66. Epub 2008 May 6.
  • Pfleiderer C, Blümel J, Schmidt M, Roth WK, Houfar MK, Eckert J, Chudy M, Menichetti E, Lechner S, Nübling CM. West Nile virus and blood product safety in Germany. J Med Virol. 2008 Mar;80(3):557-63
  • Hourfar MK, Koller M, Roth WK, Kehrli R, Seifried E, Schmidt M. Balance module allows consistent monitoring and documentation of the pooling process for nucleic acid amplification technology testing. Vox Sang. 2007 Jul;93(1):37-41.
  • Schmidt M, Nübling CM, Scheiblauer H, Chudy M, Walch LA, Seifried E, Roth WK, Hourfar MK. Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sang. 2006 Oct;91(3):237-43.
  • Schmidt M, Hourfar MK, Nicol SB, Wahl A, Heck J, Weis C, Tonn T, Spengler HP, Montag T, Seifried E, Roth WK. A comparison of three rapid bacterial detection methods under simulated real-life conditions. Transfusion. 2006 Aug;46(8):1367-73.
  • Chudy M, Schmidt M, Czudai V, Scheiblauer H, Nick S, Mosebach M, Hourfar MK, Seifried E, Roth WK, Grünelt E, Nübling CM. Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology. 2006 Jul;44(1):99-107.
  • Schmidt M, Hourfar MK, Wahl A, Nicol SB, Montag T, Roth WK, Seifried E. Fluorescence quencher improves SCANSYSTEM for rapid bacterial detection. Vox Sang. 2006 May;90(4):276-8.
  • Schmidt M, Roth WK, Seifried E, Hourfar MK. Donor screening for agents of bioterror. Transfusion. 2006 Apr;46(4):678; author reply 678-9.
  • Klose T, Kiesewetter H, Pruss A, Roth WK, Bohnen H, Friedrich I, Eck D, Putzker M. Influence of below atmospheric pressure on the pharmaceutical quality of red blood cell concentrates (RBCs) during transport and storage. Clin Lab. 2006;52(1-2):57-61.
  • Pfleiderer C, König C, Chudy M, Schmidt M, Roth WK, Nübling CM. Molecular epidemiology of West Nile Virus in humans. Dev Biol (Basel). 2006;126:197-201; discussion 326-7.
  • Schmidt M, Weis C, Heck J, Montag T, Nicol SB, Hourfar MK, Schaefer V, Sireis W, Roth WK, Seifried E. Optimized Scansystem platelet kit for bacterial detection with enhanced sensitivity: detection within 24 h after spiking. Vox Sang. 2005 Oct;89(3):135-9.
  • Hourfar MK, Schmidt M, Seifried E, Roth WK. Evaluation of an automated high-volume extraction method for viral nucleic acids in comparison to a manual procedure with preceding enrichment. Vox Sang. 2005 Aug;89(2):71-6.
  • Hourfar MK, Michelsen U, Schmidt M, Berger A, Seifried E, Roth WK. High-throughput purification of viral RNA based on novel aqueous chemistry for nucleic acid isolation. Clin Chem. 2005 Jul;51(7):1217-22.
  • Schmidt M, Weber M, Busch MP, Tobler LH, Phelps BH, Seifried E, Roth WK. Yield of hepatitis C virus nucleic acid testing among antibody-reactive or confirmed-positive samples. Transfusion.2005 Jun;45(6):1040-2.
  • Coste J, Reesink HW, Engelfriet CP, Laperche S, Brown S, Busch MP, Cuijpers HT, Elgin R, Ekermo B, Epstein JS, Flesland O, Heier HE, Henn G, Hernandez JM, Hewlett IK, Hyland C, Keller AJ, Krusius T, Levicnik-Stezina S, Levy G, Lin CK, Margaritis AR, Muylle L, Niederhauser C, Pastila S, Pillonel J, Pineau J, van der Poel CL, Politis C, Roth WK, Sauleda S, Seed CR, Sondag-Thull D, Stramer SL, Strong M, Vamvakas EC, Velati C, Vesga MA, Zanetti A. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang. 2005 May;88(4):289-303. Erratum in: Vox Sang.2005 Aug;89(2):119. Neiderhauser, C [corrected to Niederhauser, C].
  • Schmidt M, Roth WK, Meyer H, Seifried E, Hourfar MK. Nucleic acid test screening of blood donors for orthopoxviruses can potentially prevent dispersion of viral agents in case of bioterrorism. Transfusion. 2005 Mar;45(3):399-403.
  • Hourfar MK, Roth WK, Seifried E, Schmidt M. Comparison of two real-time quantitative assays for detection of severe acute respiratory syndrome coronavirus. J Clin Microbiol. 2004 May;42(5):2094-100.
  • Schmidt M, Brixner V, Ruster B, Hourfar MK, Drosten C, Preiser W, Seifried E, Roth WK. NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions. Transfusion. 2004 Apr;44(4):470-5.
  • Seifried C, Weber M, Bialleck H, Seifried E, Schrezenmeier H, Roth WK. High prevalence of GBV-C/HGV among relatives of GBV-C/HGV-positive blood donors in blood recipients and in patients with aplastic anemia. Transfusion. 2004 Feb;44(2):268-74.
  • Drosten C, Nippraschk T, Manegold C, Meisel H, Brixner V, Roth WK, Apedjinou A, Günther S. Prevalence of hepatitis B virus DNA in anti-HBc-positive/HBsAg-negative sera correlates with HCV but not HIV serostatus. J Clin Virol. 2004 Jan;29(1):59-68.
  • von Wagner M, Lee JH, Rüster B, Kronenberger B, Sarrazin C, Roth WK, Zeuzem S. Dynamics of hepatitis C virus quasispecies turnover during interferon-alpha treatment. J Viral Hepat. 2003 Nov;10(6):413-22.
  • Chudy M, Hewlett I, Saldanha J, Bianco C, Conrad AJ, Gierman T, Heldebrant C, Rautmann GG, Roth WK, Stramer S, Weimer T, Whitaker B, Zerlauth G; NAT Task Force Group. Technical considerations for the performance of Nucleic acid Amplification Technology (NAT). The NAT Task Force Group. Biologicals. 2003 Sep;31(3):153-9.
  • Klein SA, Karsten S, Rüster B, Klebba C, Pape M, Ottmann OG, Hoelzer D, Roth WK. Comparison of TaqMan real-time PCR and p24 Elisa for quantification of in vitro HIV-1 replication. J Virol Methods. 2003 Feb;107(2):169-75.
  • Roth WK, Seifried E. The German experience with NAT. Transfus Med. 2002 Aug;12(4):255-8. Review.
  • Roth WK, Weber M, Petersen D, Drosten C, Buhr S, Sireis W, Weichert W, Hedges D, Seifried E. NAT for HBV and anti-HBc testing increase blood safety. Transfusion. 2002 Jul;42(7):869-75.
  • Roth WK, Weber M, Buhr S, Drosten C, Weichert W, Sireis W, Hedges D, Seifried E. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion.2002 Jul;42(7):862-8.
  • Seifried E, Findhammer S, Roth WK. Status of NAT screening for HCV, HIV and HBV–experiences of the German Red Cross Blood Donation Services. Dev Biol (Basel). 2002;108:23-7.
  • Drosten C, Seifried E, Roth WK. TaqMan 5′-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening. J Clin Microbiol. 2001 Dec;39(12):4302-8.
  • Sarrazin C, Bruckner M, Herrmann E, Rüster B, Bruch K, Roth WK, Zeuzem S. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology. 2001 Oct 10;289(1):150-63.
  • Kronenberger B, Rüster B, Elez R, Weber S, Piiper A, Lee JH, Roth WK, Zeuzem S. Interferon alfa down-regulates CD81 in patients with chronic hepatitis C. Hepatology. 2001 Jun;33(6):1518-26.
  • Roth WK, Seifried E. Yield and future issues of nucleic acid testing. Transfus Clin Biol. 2001 Jun;8(3):282-4. Review.
  • Roth WK, Seifried E. Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT?Transfusion. 2001 Jun;41(6):845-7.
  • Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.Gastroenterology. 2001 May;120(6):1438-47.
  • Rüster B, Zeuzem S, Krump-Konvalinkova V, Berg T, Jonas S, Severin K, Roth WK. Comparative sequence analysis of the core- and NS5-region of hepatitis C virus from tumor and adjacent non-tumor tissue. J Med Virol. 2001 Feb;63(2):128-34.
  • Kronenberger B, Rüster B, Lee JH, Sarrazin C, Roth WK, Herrmann G, Zeuzem S. Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels. J Hepatol. 2000 Oct;33(4):640-7.
  • Sarrazin C, Rüster B, Lee JH, Kronenberger B, Roth WK, Zeuzem S. Prospective follow-up of patients with GBV-C/HGV infection: specific mutational patterns, clinical outcome, and genetic diversity. J Med Virol. 2000 Oct;62(2):191-8.
  • Petershofen EK, Fislage R, Faber R, Schmidt H, Roth WK, Seifried E. Detection of nucleic acid sequences from bacterial species with molecular genetic methods. Transfus Sci. 2000 Aug;23(1):21-7. 
  • Seifried E, Roth WK. Optimal blood donation screening annotation. Br J Haematol. 2000 Jun;109(4):694-8. Review.
  • Drosten C, Weber M, Seifried E, Roth WK. Evaluation of a new PCR assay with competitive internal control sequence for blood donor screening. Transfusion. 2000 Jun;40(6):718-24. 
  • Roth WK, Buhr S, Drosten C, Seifried E. NAT and viral safety in blood transfusion. Vox Sang. 2000;78 Suppl 2:257-9. Review.
© Copyright - GFE